companydirectorylist.com  Παγκόσμια Επιχειρηματικοί Οδηγοί και κατάλογοι Εταιρείας
Αναζήτηση Επιχειρήσεων , την Εταιρεία Βιομηχανίας :


Λίστες Χώρα
ΗΠΑ Κατάλογοι Εταιρεία
Καναδάς Λίστες Επιχειρήσεων
Αυστραλία Κατάλογοι επιχειρήσεων
Γαλλία Λίστες Εταιρεία
Ιταλία Λίστες Εταιρεία
Ισπανία Κατάλογοι Εταιρεία
Ελβετία Λίστες Επιχειρήσεων
Αυστρία Κατάλογοι Εταιρεία
Βέλγιο Επιχειρηματικοί Οδηγοί
Χονγκ Κονγκ Εταιρεία Λίστες
Κίνα Λίστες Επιχειρήσεων
Ταϊβάν Λίστες Εταιρεία
Ηνωμένα Αραβικά Εμιράτα Κατάλογοι Εταιρεία


Κατάλογοι Βιομηχανίας
ΗΠΑ Κατάλογοι Βιομηχανίας














  • ENJAYMO® (sutimlimab-jome) | Cold Agglutinin Disease Treatment
    ENJAYMO is the first and only FDA-approved treatment for people with cold agglutinin disease (CAD) to help decrease the need for red blood cell transfusion
  • Sutimlimab - Wikipedia
    Sutimlimab, sold under the brand name Enjaymo, is a monoclonal antibody that is used to treat adults with cold agglutinin disease (CAD) [1][3][4] It is given by intravenous infusion [1] Sutimlimab prevents complement-enhanced activation of autoimmune human B cells in vitro [5] The most common side effects include headache, high blood pressure, urinary tract infection (infection of the
  • Enjaymo: Uses, Dosage, Side Effects Warnings - Drugs. com
    Enjaymo (sutimlimab-jome) is used in the treatment cold agglutinin disease (CAD) Includes Enjaymo side effects, interactions and indications
  • HIGHLIGHTS OF PRESCRIBING INFORMATION . . .
    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ENJAYMO safely and effectively See full prescribing information for ENJAYMO ENJAYMO® (sutimlimab-jome) injection, for intravenous use Initial U S Approval: 2022
  • Enjaymo - European Medicines Agency (EMA)
    Overview Enjaymo is a medicine for treating haemolytic anaemia (excess breakdown of red blood cells) in adults with cold agglutinin disease (CAD) CAD is a rare blood disorder where the immune system (the body’s natural defence) recognises red blood cells as foreign and attacks them This causes agglutination (clumping together) and haemolysis (disruption) of the red blood cells, resulting
  • DailyMed - ENJAYMO- sutimlimab-jome injection, solution . . .
    ENJAYMO is contraindicated in patients with known hypersensitivity to sutimlimab-jome or any of the inactive ingredients [see Warnings and Precautions (5 2) and Adverse Reactions (6 1)]
  • Enjaymo (sutimlimab): Uses, Side Effects, Dosage Reviews
    Enjaymo (sutimlimab or sutimlimab-jome) is a newly-approved medication used to lower the need for blood transfusions in adults with a rare form of anemia called cold agglutinin disease (CAD) It's given as an infusion into the veins by a healthcare provider
  • Enjaymo (Sutimlimab-jome Injection): Side Effects, Uses . . .
    Enjaymo (Sutimlimab-jome Injection) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health resources




Επιχειρηματικοί Οδηγοί , Κατάλογοι Εταιρεία
Επιχειρηματικοί Οδηγοί , Κατάλογοι Εταιρεία copyright ©2005-2012 
disclaimer